Emmanuel Valentin
VP, Translational Medicine @Imcheck Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
VP, Translational Medicine @Imcheck Therapeutics
Responsible for the Precision Medicine/Biomarker strategy supporting ICT01 development:o Defined, validated and managed the multi-modal biomarker package supporting the EVICTION and EVICTION-2 clinical trials, including new relevant assays for target expression and engagement, immunophenotyping, tumor remodeling, PK/ADA and PK/PD/response modellingo Built compelling clinical data packages supporting early signs of efficacy, confirming ICT01 PoM and MoA, indications selection, and eventually leading to optimized dosingo Delivered comprehensive clinical translational data packages for regulatory submissions leading to FDA/EMA Orphan Drug Designation (Jul 2025), FDA approval of ICT01 Recommended Phase II Dose (EOP1 meeting, Aug 2025) and FDA Breakthrough Designation (Jan 2026) of ICT01 + VEN/AZA in 1L unfit AML patients
EDUCATION
Université Côte d'Azur
PhD (summa cum laude), Molecular Biology
Polytech'Nice-Sophia
Master Degree, Pharmacology
SKILLS
ABOUT EMMANUEL VALENTIN
Recognized for 25 years success in the management of R&D projects in venture-capital funded Biotech/IVD companies with strong expertise in Preclinical/Translational/Precision Medicine ResearchHighly effective in presenting scientific data to Boards and investors, at global scientific conferences,with active and successful participation in multiple financing rounds and M&A operationsExtensive understanding of biotech/pharma/IVD products development through academic/clinical collaborations and internal and externalized research, with proven track record of accelerating early clinical development (ImCheck Therapeutics) and successfully bringing products to the market (Aterovax)Author and co-author of 11 patents, and 50+ peer-reviewed publications
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.